SAB Biotherapeutics Announces Departure of Chief Financial Officer
30. Mai 2024 16:45 ET
|
SAB Biotherapeutics, Inc.
MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
21. Mai 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
20. Mai 2024 17:45 ET
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics Announces Q1 2024 Financial Results
SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors
06. Mai 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human...
SAB Biotherapeutics Provides SAB-142 Trial Update
16. April 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics provides update on SAB-142 clinical trial for type 1 diabetes
SAB Biotherapeutics to Present at INNODIA Annual Meeting
08. April 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
SAB Biotherapeutics, Inc. today announced their Chief Medical Officer will share an overview of the SAB-142 clinical development plan at INNODIA.
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference
04. April 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that...
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
29. März 2024 07:15 ET
|
SAB Biotherapeutics, Inc.
Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release...
SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment
25. März 2024 10:15 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...
SAB Biotherapeutics to Present at the BIO CEO & Investor Conference
23. Februar 2024 08:00 ET
|
SAB Biotherapeutics, Inc.
SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy...